Signature Diagnostics / Signature Diagnostics to Present Company's Newest Product in Colorectal Cancer Screening at the 35th ESMO Congress in Milan Processed and transmitted by Thomson Reuters. The issuer is solely responsible for the content of this announcement. * Blood-based screening test, Detector C/Plus, uses a panel of 1,802 RNA markers for increased sensitivity and specificity Potsdam, Germany, October 8, 2010 - Signature Diagnostics announced today that Andre Rosenthal, CEO, will present the company's newest developments in colorectal cancer (CRC) screening at the Biomarker Session of the 35(th) European Society for Medical Oncology (ESMO) Congress in Milan on October 11, 2010. The

More...